Published May 1, 2016 | Version v1
Poster Open

Flibanserin, a FDA approved dual serotonin receptor agonist-antagonist, provides retinal neuroprotection from light induced damage

Authors/Creators

  • 1. Oregon Health & Science University
  • 2. Baylor Visual Function Center
  • 3. Columbia University

Description

We assessed the neuroprotective effects of Flibanserin (BIMT-17, Addyi), a dual 5-HT1A agonist and 5-HT2A antagonist, in a light-induced retinopathy mouse model.

Files

arvo2016.pdf

Files (55.1 kB)

Name Size
md5:029a08004a0751c56a0486d114a05443
55.1 kB Preview Download